Drugs / LY-295501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00005645 | May 1999 → ? | fallopian tube cancer, metastatic malignant neoplasm, ovarian cancer, peritoneum cancer | Genzyme, a Sanofi Company | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY-295501 | ChEMBL registry synonym — accepted as the source's own label CHEMBL307177 ↗ |
| Known as | ILX-295501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005645 ↗ |
| Modality | Small molecule | — CHEMBL307177 ↗ |
| Route | Oral | “Patients receive oral ILX-295501 once weekly for 3 weeks.” NCT00005645 ↗ |